» Articles » PMID: 27830037

Goblet Cell Carcinoids of the Appendix: Tumor Biology, Mutations and Management Strategies

Overview
Specialty Gastroenterology
Date 2016 Nov 11
PMID 27830037
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant neoplasms of the appendix are rare and represent less than 1% of gastrointestinal cancers. Goblet cell carcinoids (GCC) tumors are a distinctive group of heterogeneous appendiceal neoplasm that exhibit unique clinical and pathologic features. This review focuses on the current diagnostic procedures, pathogenesis, possible signaling mechanisms and treatment options for GCC. Perspectives for future research are discussed. The tumor likely arises from pluripotent intestinal epithelial crypt base stem cells. Previous findings of Notch signaling as a tumor suppressor in Neuroendocrine tumors may have a similar role in this tumor too. Loss of Notch signaling may be the driver mutation with other successive downstream mutations likely favors them into progressing and behavior similar to poorly differentiated adenocarcinoma with minimal neuroendocrine differentiation. A multidisciplinary approach is suggested for optimal outcomes. Surgery remains the main treatment modality. Simple appendectomy may be sufficient in early stages while right hemicolectomy is recommended for advanced tumors. Cytoreductive surgery with heated intraperitoneal chemotherapy may improve survival in a select few with metastatic peritoneal disease. These tumors have an unpredictable behavior even in early stages and local recurrence and delayed metastases may be seen. Lifelong surveillance is warranted.

Citing Articles

Right Hemicolectomy and Appendicectomy as Treatments for Goblet Cell Adenocarcinoma: A Comparative Analysis of Two Large National Databases.

Asmar M, Mortagy M, Chandrakumaran K, Cecil T, Ramage J Curr Oncol. 2024; 31(7):3855-3869.

PMID: 39057157 PMC: 11276507. DOI: 10.3390/curroncol31070285.


Appendiceal Goblet Cell Carcinoma: Role of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Gaillard M, Van Eyken P, Verswijvel G, Van der Speeten K Indian J Surg Oncol. 2023; 14(Suppl 1):240-249.

PMID: 37359931 PMC: 10284751. DOI: 10.1007/s13193-023-01748-2.


Chemotherapy in the treatment of different histological types of appendiceal cancers: a SEER based study.

Wang G, Li Q, Chen W BMC Cancer. 2021; 21(1):778.

PMID: 34225672 PMC: 8259079. DOI: 10.1186/s12885-021-08502-3.


Appendiceal goblet cell carcinomas have poor survival despite completion surgery.

Alabraba E, Pritchard D, Griffin R, Diaz-Nieto R, Banks M, Cuthbertson D Endocrine. 2021; 73(3):734-744.

PMID: 33891259 DOI: 10.1007/s12020-021-02727-9.


Molecular Characterization of Appendiceal Goblet Cell Carcinoid.

Arai H, Baca Y, Battaglin F, Kawanishi N, Wang J, Soni S Mol Cancer Ther. 2020; 19(12):2634-2640.

PMID: 33037134 PMC: 8011958. DOI: 10.1158/1535-7163.MCT-20-0318.


References
1.
Koo B, Clevers H . Stem cells marked by the R-spondin receptor LGR5. Gastroenterology. 2014; 147(2):289-302. DOI: 10.1053/j.gastro.2014.05.007. View

2.
Bucher P, Gervaz P, Ris F, Oulhaci W, Egger J, Morel P . Surgical treatment of appendiceal adenocarcinoid (goblet cell carcinoid). World J Surg. 2005; 29(11):1436-9. DOI: 10.1007/s00268-005-7958-y. View

3.
Cheng H, Leblond C . Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. I. Columnar cell. Am J Anat. 1974; 141(4):461-79. DOI: 10.1002/aja.1001410403. View

4.
Byrn J, Wang J, Divino C, Nguyen S, Warner R . Management of goblet cell carcinoid. J Surg Oncol. 2006; 94(5):396-402. DOI: 10.1002/jso.20587. View

5.
Yang Q, Bermingham N, Finegold M, Zoghbi H . Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science. 2001; 294(5549):2155-8. DOI: 10.1126/science.1065718. View